Breadcrumb Home Studies Studies Search Filter Research Area AllComplications & ComorbiditiesCureTreatmentTuberculosis Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentOpen to AccrualParticipants Off Study and Primary Analysis CompletedPendingTemporarily Closed (Paused) to Accrual and Study Agents/ProductsWithdrawn Sort Study Number AscStudy Number Desc Submit Search Showing 123 studies. ACTG 5418: A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Monkeypox Virus Disease A5257: Study of Three Compact ARV Regimens for Treatment of Naive HIV-1 Volunteers DAIDS Number 10670 Research Area Antiretroviral Strategies Study Status Concluded A5241: Identifying Salvage Regimen w/ & w/o NRTIs Using cPSS and New Agents in the US DAIDS Number 10395 Research Area Antiretroviral Strategies Study Status Concluded IMPAACT 2040: Phase I/II Pharmacokinetics and safety of long-acting injectable Cabotegravir and Rilpivirine in people with virally suppressed HIV-1 during pregnancy and postpartum DAIDS Number TBD Research Area Treatment Study Status In Development IMPAACT 2039: Phase I/II Study of the Safety, Immunogenicity, Efficacy of HIVconsvX Vaccines in Children Living with HIV DAIDS Number TBD Research Area Cure Study Status In Development IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 DAIDS Number 38962 Research Area Treatment Study Status In Development IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Treatment Study Status Pending IMPAACT 2035/HVTN 604: Phase I/II Randomized, Placebo-Controlled Study of the Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination against Tuberculosis in Pre-Adolescents Living with and without HIV in South Africa (LEAP) DAIDS Number 38846 Research Area Tuberculosis Study Status Pending IMPAACT 2034: Phase I Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Pending IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States DAIDS Number 38746 Research Area Treatment Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Page 13 Next page Next
ACTG 5418: A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Monkeypox Virus Disease
A5257: Study of Three Compact ARV Regimens for Treatment of Naive HIV-1 Volunteers DAIDS Number 10670 Research Area Antiretroviral Strategies Study Status Concluded
A5241: Identifying Salvage Regimen w/ & w/o NRTIs Using cPSS and New Agents in the US DAIDS Number 10395 Research Area Antiretroviral Strategies Study Status Concluded
IMPAACT 2040: Phase I/II Pharmacokinetics and safety of long-acting injectable Cabotegravir and Rilpivirine in people with virally suppressed HIV-1 during pregnancy and postpartum DAIDS Number TBD Research Area Treatment Study Status In Development
IMPAACT 2039: Phase I/II Study of the Safety, Immunogenicity, Efficacy of HIVconsvX Vaccines in Children Living with HIV DAIDS Number TBD Research Area Cure Study Status In Development
IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 DAIDS Number 38962 Research Area Treatment Study Status In Development
IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Treatment Study Status Pending
IMPAACT 2035/HVTN 604: Phase I/II Randomized, Placebo-Controlled Study of the Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination against Tuberculosis in Pre-Adolescents Living with and without HIV in South Africa (LEAP) DAIDS Number 38846 Research Area Tuberculosis Study Status Pending
IMPAACT 2034: Phase I Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Pending
IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States DAIDS Number 38746 Research Area Treatment
